Funded Startups in Kangwon-do
Among the 5 most recent rounds in Kangwon-do with disclosed amounts, April Bio’s $124M (2026-06-25) is a clear outlier: it is the only disclosed round abov…
Among the 5 most recent rounds in Kangwon-do with disclosed amounts, April Bio’s $124M (2026-06-25) is a clear outlier: it is the only disclosed round above $50M, while the next-largest disclosed amount is Caring’s $27M (2026-05-08). Smaller disclosed checks cluster in the teens to high-$20s range, including NEUROPHET’s $11M (2026-04-10).
The list is also temporally concentrated: all 5 rounds fall between 2026-04-10 and 2026-06-25, with 3 closings between 2026-04-10 and 2026-05-08. Sector coverage is mixed, but “Series Unknown” appears in 3 of 5 entries (April Bio, Selectica, Elice, and NEUROPHET account for the three classifications shown; Caring is the lone Series C), alongside 2 rows marked “undisclosed” (Selectica and Elice). By geography, Gangneung appears repeatedly (Caring, Elice, NEUROPHET), indicating a local concentration around that city within this short window.
Most recent rounds
5 shownRelated listings
Frequently asked
What’s the largest disclosed round in this Kangwon-do slice, and how does it compare to the other disclosed amounts?
April Bio’s $124M (2026-06-25) is the only disclosed round above $50M in the 5-row view. The next-largest disclosed amount is Caring’s $27M (2026-05-08), with NEUROPHET at $11M (2026-04-10) and the remaining disclosed amounts not exceeding that higher-$20s level.
Are there noticeable city or sector clusters in the most recent entries?
Gangneung shows up three times: Caring (2026-05-08, $27M), Elice (2026-04-13, undisclosed), and NEUROPHET (2026-04-10, $11M). Sector-wise, the entries are spread (Biotechnology, Community and Lifestyle, Education, AI, plus “Other”), with no single sector repeating across 3+ rows.
Which rounds landed in the tightest part of the timeline (roughly the last 60–70 days shown)?
From 2026-05-08 through 2026-06-25, there are two entries: Caring on 2026-05-08 ($27M) and April Bio on 2026-06-25 ($124M). The other three entries fall earlier within the window—NEUROPHET (2026-04-10, $11M), Elice (2026-04-13, undisclosed), and Selectica (2026-06-18, undisclosed).
How does stage classification break down, and does it align with the disclosed amounts?
Only one entry is labeled “Series C” (Caring, 2026-05-08, $27M). “Series Unknown” appears in 4 of 5 entries (April Bio, Selectica, Elice, NEUROPHET), and among the disclosed subset, April Bio ($124M) and Caring ($27M) are the highest disclosed amounts while Selectica and Elice are marked “undisclosed.”
Are there outliers besides the largest round—particularly around disclosure levels?
Yes: two entries are marked “undisclosed” (Selectica on 2026-06-18 and Elice on 2026-04-13), creating a disclosure split versus the disclosed amounts ($124M, $27M, and $11M). April Bio’s $124M (2026-06-25) is the standout magnitude outlier relative to the rest of the disclosed figures.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.